Want to see ELDN full AI Analyst Report?
ELDN Stock Chart & Stats
$3.58
-$0.02(-0.56%)
At close: 4:00 PM EDT
$3.58
-$0.02(-0.56%)
Day’s Range― - ―
52-Week Range$1.35 - $4.60
Previous CloseN/A
Volume630.04K
Average Volume (3M)1.57M
Market Cap
$284.05M
Enterprise Value$291.43
Total Cash (Recent Filing)$111.09M
Total Debt (Recent Filing)$555.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding77,187,820
10 Day Avg. Volume888,396
30 Day Avg. Volume1,569,320
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside165.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt reduces insolvency risk and gives management financial flexibility to fund R&D and clinical programs without immediate refinancing pressure. This structural strength supports multi-stage clinical development timelines and strategic optionality over the next 2–6 months.
Expanded Share Authorization & GovernanceIncreasing authorized shares and recent director elections reinforce capital-raising and governance capacity. Structurally, it enables planned financings or strategic transactions, reducing execution friction for future funding or partnerships as clinical programs advance.
Improving Free Cash Flow TrendAlthough FCF remains negative, a positive growth rate versus the prior year indicates early traction in slowing cash burn or improving operational efficiency. If sustained, this trend can materially extend runway and reduce near-term financing needs.
Bears Say
Pre-Revenue OperationsAs a clinical-stage biotech with no product revenue, the company must rely on external funding until commercialization or partnerships deliver revenue. This structural lack of revenue prolongs dependence on capital markets and increases execution risk over the medium term.
High Cash BurnSustained ~-$69M TTM operating/free cash flow implies heavy ongoing cash consumption to fund trials and operations. Structurally, this necessitates recurring financings that can dilute shareholders or constrain program funding if market access tightens.
Dilution & Equity Erosion RiskExpanded share authorization combined with ongoing losses increases the probability of equity issuance. Over time, repeated financings could erode existing equity value and reduce per-share economics for investors unless development milestones or partner revenues offset dilution.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals, Inc.’s price range in the past 12 months?
Eledon Pharmaceuticals, Inc. lowest stock price was $1.35 and its highest was $4.60 in the past 12 months.
What is Eledon Pharmaceuticals, Inc.’s market cap?
Eledon Pharmaceuticals, Inc.’s market cap is $284.05M.
When is Eledon Pharmaceuticals, Inc.’s upcoming earnings report date?
Eledon Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 98 days.
How were Eledon Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Eledon Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Eledon Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Eledon Pharmaceuticals, Inc. pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
What is Eledon Pharmaceuticals, Inc.’s EPS estimate?
Eledon Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eledon Pharmaceuticals, Inc. have?
Eledon Pharmaceuticals, Inc. has 77,187,820 shares outstanding.
What happened to Eledon Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eledon Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (165.36% Upside)
$9.50 (165.36% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 70.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$9.50
▲(165.36% Upside)
Technical Analysis
Ownership Overview
0.36% Insiders
8.04% Mutual Funds
1.37% Other Institutional Investors
80.08% Public Companies and
Individual Investors